Skip to main content

Immunological incompatibility as a basis for cancer curing and vaccination

Objective

In the ULISES project, we aim at developing an immunologic-based treatment strategy where cancer cells are “reprogrammed” to become “visible” to the patient’s own immune system, which will see them as “not belonging to the body” and will attack them, emulating the allogenic response to incompatible transplants. Thus, it will constitute a “natural” treatment, as the patient’s own immune system will be used to attack cancer cells, with no drugs, chemotherapy, radiotherapy, transplants, etc., significantly reducing the treatment time to few weeks and producing minimal or almost null side effects. In addition, this “reprogramming” will lead to an “immunological-memory” avoiding future relapses (vaccine-like effect) through TIL (Tumour Infiltrating Lymphocytes) generated around the tumour microenvironment by the immune system.
Porous nanoparticles (NPs) will be used as carriers for delivering a plasmid DNA cargo into the tumour cells in order to produce that “reprogramming”. These NPs will specifically recognize the cancer cells through the CD47 protein and the folate receptors beta and alpha, highly expressed on the surface of the cells. Moreover, two messenger RNAs will be used in order to avoid the side effects caused by targeting CD47 protein (mainly anaemia, neutropenia and thrombocytopenia).
Finally, highlight that the ULISES therapeutic strategy will be a “global” treatment, since only with 3 subtypes of NP (one for each chosen alloHLA-A), we will be able to target the entire population for each cancer type. For the implementation and validation of this strategy, we will focus on pancreatic cancer because of its high aggressiveness, lack of effective treatments and little life expectancy, but the developed strategy will also be valid for other cancer varieties with minimal modifications.

Field of science

  • /medical and health sciences/basic medicine/immunology
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-FETOPEN-2018-2019-2020-01
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Address
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Spain
Activity type
Other
EU contribution
€ 454 561

Participants (9)

VICTOR PALLARUELO-SANTAMARIA
Spain
EU contribution
€ 35 001,50
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 244 167,50
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 311 667,50
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
Spain
EU contribution
€ 239 376,25
Address
Calle Luis Fontes Pagan 9 Edif Emi Hospital Reina Sofia
30003 Murcia
Activity type
Research Organisations
Fundación Instituto Valenciano de Oncología
Spain
EU contribution
€ 389 792,50
Address
Beltrán Báguena 8
46009 Valencia
Activity type
Research Organisations
DELPHI GENETICS
Belgium
EU contribution
€ 648 542,50
Address
Rue Antoine De Saint Exupery 5
6041 Charleroi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PIRCHE AG
Germany
EU contribution
€ 149 583,75
Address
Stuttgarter Platz 2
10627 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAT POLITECNICA DE VALENCIA
Spain
EU contribution
€ 334 550
Address
Camino De Vera Sn Edificio 3A
46022 Valencia
Activity type
Higher or Secondary Education Establishments
FONDAZIONE ICONS
Italy
EU contribution
€ 169 917,50
Address
Piazza Della Vittoria 1
26900 Lodi
Activity type
Other